CIMO

CIMO is a synthetic N-substituted azaspirane derivative that acts as a potent inhibitor of the JAK-STAT3 signaling pathway. It specifically targets the phosphorylation of Signal transducer and activator of transcription 3 (STAT3) at the Tyrosine 705 (Tyr-705) residue, thereby preventing its dimerization, nuclear translocation, and subsequent transcriptional activity. By inhibiting upstream kinases such as Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and c-Src, CIMO down-regulates the expression of various oncogenic target genes involved in cell cycle progression (cyclin D1), apoptosis resistance (Bcl-2, Bcl-xL, survivin), and metastasis. Preclinical studies in hepatocellular carcinoma (HCC) models have demonstrated that CIMO induces cytotoxicity, inhibits cell migration and invasion, and significantly reduces tumor growth in vivo.

Other names

2-(1-(4-(2-cyanophenyl)1-benzyl-1H-indol-3-yl)-5-(4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5) undecane